CGON CG Oncology, Inc. Common stock

$42.55

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/18/2025

About CG Oncology, Inc. Common stock

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1991792
Address
400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE, CA, UNITED STATES
Valuation
Market Cap
$1.57B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.15
Performance
EPS
$-1.41
Dividend Yield
—
Profit Margin
0.00%
ROE
-19.20%
Technicals
50D MA
$24.97
200D MA
$31.69
52W High
$46.99
52W Low
$14.80
Fundamentals
Shares Outstanding
76M
Target Price
$62.38
Beta
nan

CGON EPS Estimates vs Actual

● Estimated
● Actual

CGON News & Sentiment

Nov 17, 2025 • Zacks Commentary NEUTRAL
Company News for Nov 17, 2025
Companies in The News Are: ...
Nov 14, 2025 • Zacks Commentary NEUTRAL
CG Oncology, Inc. ( CGON ) Reports Q3 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of 0.00% and +412.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 14, 2025 • Business Insider SOMEWHAT-BULLISH
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
Initiated rolling Biologics License Application ( BLA ) submission to U.S. FDA for cretostimogene monotherapy in high-risk ( HR ) BCG-unresponsive non-muscle invasive bladder cancer ( NMIBC )
Nov 14, 2025 • GlobeNewswire NEUTRAL
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
IRVINE, Calif., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc. ( NASDAQ: CGON ) , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results ...
Nov 06, 2025 • Zacks Commentary NEUTRAL
ProQR ( PRQR ) Reports Q3 Loss, Misses Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -20.00% and -60.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 08, 2025 • Motley Fool SOMEWHAT-BULLISH
Why Cg Oncology Stock Rocketed 7% Higher Today
One pundit believes this is a clinical-stage company well worth watching.
Sentiment Snapshot

Average Sentiment Score:

0.083
50 articles with scored sentiment

Overall Sentiment:

Neutral

CGON Reported Earnings

Aug 08, 2025
Jun 30, 2025 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.54
  • Estimate: $-0.44
  • Whisper: —
  • Surprise %: -22.1%
May 13, 2025
Mar 31, 2025 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.45
  • Estimate: $-0.37
  • Whisper: —
  • Surprise %: -20.3%
Mar 28, 2025
Dec 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.46
  • Estimate: $-0.45
  • Whisper: —
  • Surprise %: -2.2%
Nov 14, 2024
Sep 30, 2024 (Pre market)
0.12 Surprise
  • Reported EPS: $-0.30
  • Estimate: $-0.42
  • Whisper: —
  • Surprise %: 28.6%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.12 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 30.0%
May 09, 2024
Mar 31, 2024 (Pre market)
-0.07 Surprise
  • Reported EPS: $-0.36
  • Estimate: $-0.29
  • Whisper: —
  • Surprise %: -24.1%
Mar 26, 2024
Dec 31, 2023 (Pre market)
0.34 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.67
  • Whisper: —
  • Surprise %: 50.6%

Financials